5d 1m 3m 1y 5y 10y
There are no Transcripts on CLDN.
GlobeNewswire (Mar 5, 2014)
GlobeNewswire (Mar 4, 2014)
Celladon Corporation Announces Appointments of Dr. Peter Honig and Dr. Patrick Yang to Its Board of DirectorsGlobeNewswire (Mar 3, 2014)
Celladon Announces Exercise in Full and Closing of Underwriters' Option to Purchase Additional SharesGlobeNewswire (Feb 27, 2014)
GlobeNewswire (Feb 24, 2014)
CLDN vs. ETF Alternatives
Celladon Corp develops treatments for heart failure, diabetes and neurodegenerative diseases. Its lead product candidate, MYDICAR, uses gene therapies to target SERCA2a, an enzyme that becomes deficient in patients with heart failure.